ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout FlaresGlobeNewsWire • 05/22/25
ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQGlobeNewsWire • 05/12/25
Compared to Estimates, ANI (ANIP) Q1 Earnings: A Look at Key MetricsZacks Investment Research • 05/09/25
ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 GuidanceGlobeNewsWire • 05/09/25
ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards?Zacks Investment Research • 05/05/25
ANI Pharmaceuticals Announces Presentation of Preclinical Data on the Use of Purified Cortrophin® Gel in an Experimental Autoimmune Uveitis (EAU) Mouse ModelGlobeNewsWire • 05/05/25
Buy 4 Low-Beta Stocks ANIP, LRN, MASS & CTGO as Tariff Woes ContinueZacks Investment Research • 04/23/25
ANI Pharmaceuticals, Inc. (ANIP) Soars to 52-Week High, Time to Cash Out?Zacks Investment Research • 04/17/25
ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ETGlobeNewsWire • 04/09/25
Tariff Woes? Play Safe With 4 Low-Beta Stocks: ANIP, EXE, AVA & CTGOZacks Investment Research • 04/07/25
Is the Options Market Predicting a Spike in ANI Pharmaceuticals (ANIP) Stock?Zacks Investment Research • 04/03/25
ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual ConferenceGlobeNewsWire • 03/31/25
Wall Street Analysts Think ANI (ANIP) Could Surge 26.83%: Read This Before Placing a BetZacks Investment Research • 03/24/25
ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN® and YUTIQ®GlobeNewsWire • 03/18/25